Investigational drug · Phase 2
PUL-042
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "PUL-042"
First trial start
2025
Jun 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PUL-042", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hematologic Malignancies
- Hematopoietic Stem Cell Transplant (HSCT)
Largest trials
Live from ClinicalTrials.gov: studies naming "PUL-042" as an intervention, largest first.
- The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2Pivotal-lookingCompleted
Pulmotect, Inc.Industry
NCT04313023 · 217 participants · Start Jun 9, 2020 · Primary completion Jul 31, 2021
Drug: PUL-042 Inhalation Solution; Placebo · For: COVID-19
Sites: Orange, California; San Bernardino, California; Coral Gables, Florida · 15 sites in all
- The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 InfectionPivotal-lookingCompleted
Pulmotect, Inc.Industry
NCT04312997 · 101 participants · Start Jun 16, 2020 · Primary completion Jul 2, 2021
Drug: PUL-042 Inhalation Solution; Placebo · For: COVID-19
Sites: Orange, California; San Bernardino, California; Coral Gables, Florida · 11 sites in all
- PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)Pivotal-lookingRecruiting
Pulmotect, Inc.Industry
NCT06665100 · 100 participants (planned) · Start Jun 27, 2025 · Primary completion Apr 2027
Drug: PUL-042; Placebo · For: Hematologic Malignancies; Hematopoietic Stem Cell Transplant (HSCT)
Sites: Duarte, California; Atlanta, Georgia; Baltimore, Maryland · 12 sites in all
- Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy SubjectsCompleted
Pulmotect, Inc.Industry
NCT02124278 · 42 participants · Start Feb 2014 · Primary completion Oct 2014
Drug: PUL-042 Inhalation Solution · For: Healthy
Sites: San Antonio, Texas
- The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPDCompleted
Pulmotect, Inc.Industry
NCT03794557 · 20 participants · Start Jan 21, 2019 · Primary completion Dec 16, 2020
Drug: Sterile Water Injection; PUL-042 Inhalation Solution · For: COPD
Sites: London, United Kingdom
Pulmotect, Inc.Industry
NCT02566252 · 16 participants · Start Jul 2015 · Primary completion Jan 2016
Drug: PUL-042 Inhalation Solution; Cromolyn Sodium and 1 more · For: Healthy
Sites: Cypress, California
Pulmotect, Inc.Industry
NCT03097796 · 0 participants · Start Dec 2024 · Primary completion Mar 2026
Drug: PUL-042 · For: Hematologic Diseases; Stem Cell Transplants
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Host-directed therapy in foals can enhance functional innate immunity and reduce severity of Rhodococcus equi pneumonia.
Bordin AI, Cohen ND, Giguère S, et al. · Sci Rep 2021
- Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
Leiva-Juarez MM, Kirkpatrick CT, Gilbert BE, et al. · Eur J Pharmacol 2018
Also in development for Hematologic Malignancies
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- ICP-248MesutoclaxPhase 35 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Relapsed or Refractory Mantle Cell Lymphoma (MCL), Acute Myeloblastic Leukemia, Relapsed/Refractory Marginal Zone Lymphoma (MZL)
- coformulation favezelimabMK-4280APhase 33 trials
Merck & Co. · Small Cell Lung Carcinoma, Solid Tumors, Hematologic Malignancies
- GFH009SLS009Phase 22 trials
Genfleet Therapeutics (Shanghai) Inc. · Large B-cell Lymphoma, Hematologic Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.